MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AML

Randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AMLПодробнее

Finding the Key to Better Outcomes in FLT3-Mutated AMLПодробнее

Gilteritinib for FLT3-Mutant AMLПодробнее

Role of FLT3 Inhibitors and Other Novel Agents in AMLПодробнее

FLT3 Inhibitors in the Therapy of Acute Myeloid LeukemiaПодробнее

Gilteritinib maintenance after allogeneic transplantation in FLT3-mutated AMLПодробнее

QuANTUM-First: FLT3-ITD-specific MRD to assess benefits of quizartinib in FLT3-ITD+ AMLПодробнее

The value of FLT3 inhibitors in AML and focus for future trial designsПодробнее

FLT3 inhibitors as maintenance therapy in AMLПодробнее

COSTEM AML highlights: SCT & MRD status, sorafenib maintenance & gilteritinib in FLT3+ AMLПодробнее

Novel FLT3 inhibitors for AMLПодробнее

Significance of Minimal Residual Disease in Acute Myeloid LeukemiaПодробнее

Acute Myeloid Leukemia and the Role of FLT3 Inhibitors: Best Practices for the Interprofessional ...Подробнее

Novel treatment combinations for FLT3-mutated AMLПодробнее

Targeted therapies in newly diagnosed AML: BCL2, FLT3 and IDH inhibitorsПодробнее

getITD for FLT3-ITD-based MRD monitoring in AMLПодробнее

Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitorsПодробнее

The use of FLT3 inhibitors in AMLПодробнее

FLT3 inhibitors for treating AMLПодробнее